Trial Profile
Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Final results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Mar 2023 Planned End Date changed from 20 Jul 2023 to 20 Sep 2024.